<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328677</url>
  </required_header>
  <id_info>
    <org_study_id>6407</org_study_id>
    <nct_id>NCT02328677</nct_id>
    <nct_alias>NCT02391597</nct_alias>
  </id_info>
  <brief_title>ColoCare Study - Colorectal Cancer Cohort</brief_title>
  <official_title>ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntsman Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ColoCare is an international prospective cohort study of stage I-IV colorectal cancer
      patients (ICD-10 C18-C20).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ColoCare Consortium is a multicenter initiative establishing an international cohort of
      colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes
      with sites at the Fred Hutchinson Cancer Research Center, Seattle (Washington, USA), H. Lee
      Moffitt Cancer Center and Research Institute, Tampa (Florida, USA), the University Hospital
      Heidelberg (Germany), the Huntsman Cancer Institute (Utah, USA), the Cedars-Senai Medical
      Center (California, USA), University of Washington St. Louis (Missouri, USA), and University
      of Tennessee (Tennessee, USA).

      Aims: The ColoCare Study investigates clinical outcomes, including disease-free and overall
      survival, predictors of cancer recurrence, survival, health-related quality-of-life and
      treatment toxicities. In addition, cross-sectional analyses of biomarkers and/or health
      behaviors are undertaken.

      Patients are recruited at baseline (time of first diagnosis) and followed for up to 5 years
      at regular timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive
      collection of specimens and data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free and overall survival</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>at 0, 3, 6, 12, 24, 36, 48, 60 months post recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicities</measure>
    <time_frame>up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ColoCare FHCRC</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n= 389</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ColoCare Moffitt (affiliated cohort)</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=508</description>
  </arm_group>
  <arm_group>
    <arm_group_label>University Hospital Heidelberg</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=590</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ColoCare Huntsman Cancer Institute</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=96</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cedars-Sinai Medical Center</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>University of Washington St. Louis</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>University of Tennessee</arm_group_label>
    <description>Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status June 2017: n=20</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, feces, saliva, FFPE and fresh frozen tissue (multiple sources/locations) from
      the tumor, DNA, RNA, miRNA, visceral adipose tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ColoCare is an international prospective cohort study of stage I-IV colorectal cancer
        patients (ICD-10 C18-C20). The ColoCare Consortium is a multicenter initiative of
        interdisciplinary research on CRC outcome and prognosis, and comprises patient recruitment
        at 6 sites. Patients are recruited at baseline (time of first diagnosis, time prior to
        surgery or during treatment (FHCRC and HCI)) and followed for up to 10 years at regular
        timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive
        collection of biospecimens and data.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-89 years;

          2. Men and Women

          3. Newly-diagnosed colon or rectal cancer (stages I-IV); CRC in treatment (FHCRC and HCI)

          4. English (FHCRC, Moffitt, HCI, Cedars-Senai, UW St. Louis, UT) or German (University
             Hospital Heidelberg)-speaking;

          5. mentally/physically able to consent and participate.

        Exclusion Criteria:

          -  if one of the above in not fulfilled

          -  insufficient language or consent capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia M Ulrich, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Grady, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexis Ulrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erin Siegel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lee H. Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Figueireido, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Senai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Shibata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennesee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adetunji T. Toriola, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington St. Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cornelia Ulrich, MS, PhD</last_name>
    <phone>(801) 213-5716</phone>
    <email>neli.ulrich@hci.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Siegel, MD</last_name>
    <phone>813-745-6533</phone>
    <email>erin.siegel@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Senai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Figueiredo, PhD</last_name>
      <email>janefigu@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lee H. Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>12902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Siegel, PhD</last_name>
      <email>Erin.siegel@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adetunji T Toriola, MD, PhD</last_name>
      <email>a.toriola@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37996</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Shibata, MD</last_name>
      <email>dshibata@uthsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Ulrich, MS, PhD</last_name>
      <email>neli.ulrich@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FHCRC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Li, MD, PhD</last_name>
      <email>cili@fhcrc.org</email>
    </contact>
    <contact_backup>
      <last_name>William Grady, MD, PhD</last_name>
      <email>wgrady@fhcrc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Ulrich, MD</last_name>
      <email>alexis.ulrich@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Clark W, Siegel EM, Chen YA, Zhao X, Parsons CM, Hernandez JM, Weber J, Thareja S, Choi J, Shibata D. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg. 2013 Jun;216(6):1070-81. doi: 10.1016/j.jamcollsurg.2013.01.007. Epub 2013 Mar 21.</citation>
    <PMID>23523147</PMID>
  </results_reference>
  <results_reference>
    <citation>Ulrich CM, Toriola AT, Siegel EM, Brenner H, Chang-Claude J, Abbenhardt C, Kotzmann J, Song X, Owen RW, Hoffmeister M, Becher H, Shibata D, Vickers K, Rush SK, Makar K, Würtele G, Haubner R, Sellers TA, Grady W. Plasma 25-hydroxyvitamin D3, folate and vitamin B12 biomarkers among international colorectal cancer patients: a pilot study. J Nutr Sci. 2013 Apr 9;2:e9. doi: 10.1017/jns.2012.28. eCollection 2013.</citation>
    <PMID>25191595</PMID>
  </results_reference>
  <results_reference>
    <citation>Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, Herpel E, Kloor M, Ulrich A, Schneider M, Ulrich CM, Robins H. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother. 2013 Sep;62(9):1453-61. doi: 10.1007/s00262-013-1446-2. Epub 2013 Jun 16.</citation>
    <PMID>23771160</PMID>
  </results_reference>
  <results_reference>
    <citation>Luo Y, Wong CJ, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, Wang J, Willis JE, Makar KW, Ulrich CM, Lutterbaugh JD, Shrubsole MJ, Zheng W, Markowitz SD, Grady WM. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology. 2014 Aug;147(2):418-29.e8. doi: 10.1053/j.gastro.2014.04.039. Epub 2014 Apr 30.</citation>
    <PMID>24793120</PMID>
  </results_reference>
  <results_reference>
    <citation>Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I, Bork P. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014 Nov 28;10:766. doi: 10.15252/msb.20145645.</citation>
    <PMID>25432777</PMID>
  </results_reference>
  <results_reference>
    <citation>Ristau J, Staffa J, Schrotz-King P, Gigic B, Makar KW, Hoffmeister M, Brenner H, Ulrich A, Schneider M, Ulrich CM, Habermann N. Suitability of circulating miRNAs as potential prognostic markers in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2632-7. doi: 10.1158/1055-9965.EPI-14-0556.</citation>
    <PMID>25472670</PMID>
  </results_reference>
  <results_reference>
    <citation>Skender S, Schrotz-King P, Böhm J, Abbenhardt C, Gigic B, Chang-Claude J, Siegel EM, Steindorf K, Ulrich CM. Repeat physical activity measurement by accelerometry among colorectal cancer patients--feasibility and minimal number of days of monitoring. BMC Res Notes. 2015 Jun 6;8:222. doi: 10.1186/s13104-015-1168-y.</citation>
    <PMID>26048683</PMID>
  </results_reference>
  <results_reference>
    <citation>Liesenfeld DB, Grapov D, Fahrmann JF, Salou M, Scherer D, Toth R, Habermann N, Böhm J, Schrotz-King P, Gigic B, Schneider M, Ulrich A, Herpel E, Schirmacher P, Fiehn O, Lampe JW, Ulrich CM. Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study. Am J Clin Nutr. 2015 Aug;102(2):433-43. doi: 10.3945/ajcn.114.103804. Epub 2015 Jul 8.</citation>
    <PMID>26156741</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Albeniz X, Rudolph A, Hutter C, White E, Lin Y, Rosse SA, Figueiredo JC, Harrison TA, Jiao S, Brenner H, Casey G, Hudson TJ, Thornquist M, Le Marchand L, Potter J, Slattery ML, Zanke B, Baron JA, Caan BJ, Chanock SJ, Berndt SI, Stelling D, Fuchs CS, Hoffmeister M, Butterbach K, Du M, James Gauderman W, Gunter MJ, Lemire M, Ogino S, Lin J, Hayes RB, Haile RW, Schoen RE, Warnick GS, Jenkins MA, Thibodeau SN, Schumacher FR, Lindor NM, Kolonel LN, Hopper JL, Gong J, Seminara D, Pflugeisen BM, Ulrich CM, Qu C, Duggan D, Cotterchio M, Campbell PT, Carlson CS, Newcomb PA, Giovannucci E, Hsu L, Chan AT, Peters U, Chang-Claude J. CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer. 2016 Jan 19;114(2):221-9. doi: 10.1038/bjc.2015.443. Epub 2016 Jan 14.</citation>
    <PMID>26766742</PMID>
  </results_reference>
  <results_reference>
    <citation>Skender S, Ose J, Chang-Claude J, Paskow M, Brühmann B, Siegel EM, Steindorf K, Ulrich CM. Accelerometry and physical activity questionnaires - a systematic review. BMC Public Health. 2016 Jun 16;16:515. doi: 10.1186/s12889-016-3172-0. Review.</citation>
    <PMID>27306667</PMID>
  </results_reference>
  <results_reference>
    <citation>Böhm J, Pianka F, Stüttgen N, Rho J, Gigic B, Zhang Y, Habermann N, Schrotz-King P, Abbenhardt-Martin C, Zielske L, Lampe PD, Ulrich A, Diener MK, Ulrich CM. Discovery of novel plasma proteins as biomarkers for the development of incisional hernias after midline incision in patients with colorectal cancer: The ColoCare study. Surgery. 2017 Mar;161(3):808-817. doi: 10.1016/j.surg.2016.08.025. Epub 2016 Oct 13.</citation>
    <PMID>27745870</PMID>
  </results_reference>
  <results_reference>
    <citation>Gong J, Hutter CM, Newcomb PA, Ulrich CM, Bien SA, Campbell PT, Baron JA, Berndt SI, Bezieau S, Brenner H, Casey G, Chan AT, Chang-Claude J, Du M, Duggan D, Figueiredo JC, Gallinger S, Giovannucci EL, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hudson TJ, Jeon J, Jenkins MA, Kocarnik J, Küry S, Le Marchand L, Lin Y, Lindor NM, Nishihara R, Ogino S, Potter JD, Rudolph A, Schoen RE, Schrotz-King P, Seminara D, Slattery ML, Thibodeau SN, Thornquist M, Toth R, Wallace R, White E, Jiao S, Lemire M, Hsu L, Peters U; CCFR and GECCO. Genome-Wide Interaction Analyses between Genetic Variants and Alcohol Consumption and Smoking for Risk of Colorectal Cancer. PLoS Genet. 2016 Oct 10;12(10):e1006296. doi: 10.1371/journal.pgen.1006296. eCollection 2016 Oct.</citation>
    <PMID>27723779</PMID>
  </results_reference>
  <results_reference>
    <citation>Nattenmueller J, Hoegenauer H, Boehm J, Scherer D, Paskow M, Gigic B, Schrotz-King P, Grenacher L, Ulrich C, Kauczor HU. CT-based compartmental quantification of adipose tissue versus body metrics in colorectal cancer patients. Eur Radiol. 2016 Nov;26(11):4131-4140. Epub 2016 Feb 6.</citation>
    <PMID>26852215</PMID>
  </results_reference>
  <results_reference>
    <citation>Skender S, Böhm J, Schrotz-King P, Chang-Claude J, Siegel EM, Steindorf K, Owen RW, Ose J, Hoffmeister M, Brenner H, Ulrich CM. Plasma 25-Hydroxyvitamin D(3) Levels in Colorectal Cancer Patients and Associations with Physical Activity. Nutr Cancer. 2017 Feb-Mar;69(2):229-237. doi: 10.1080/01635581.2017.1265131. Epub 2017 Jan 17.</citation>
    <PMID>28094599</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozoya OO, Siegel EM, Srikumar T, Bloomer AM, DeRenzis A, Shibata D. Quantitative Assessment of Visceral Obesity and Postoperative Colon Cancer Outcomes. J Gastrointest Surg. 2017 Mar;21(3):534-542. doi: 10.1007/s11605-017-3362-9. Epub 2017 Jan 18.</citation>
    <PMID>28101721</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Cornelia</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>rectosigmoid</keyword>
  <keyword>rectum</keyword>
  <keyword>colon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

